CRISPR technology will allow AstraZeneca to identify and validate new drug targets in preclinical models that closely resemble human disease.

ResourcesVideosCRISPRDrug discoveryGenetic engineeringGenomic medicineNovel targets identificationSequencingAstraZeneca
Previous articleStrategic Cell-Line Development
Next articleWith $10M NIMH Grant, UC Davis Establishes Schizophrenia Center
Also of Interest
Blood Biomarker Reveals Signs of Multiple Sclerosis Years Before
StockWatch: PacBio Faces Uphill Climb as Q1 Revenue Falls Short
Gene Network Interactions Shed Insight into Breast Cancer Onset and Development
At Bio-IT World 2024, AI Applications Take Center Stage
SPARDA: A Programmable Nucleic Acid Targeting Technology Like CRISPR
New Insights Could Boost Immunotherapy for Rare Eye Cancer
Related Media
Sickle Cell Salvation: The Victoria Gray Interview
Sun, Spatial, and Sequencing: A Video Report from the First Day of AGBT
Perfect Pitch: Genome Editing Pioneer Fyodor Urnov on Commercializing CRISPR Therapies and Epigenomic Tuning
Carl Icahn States His Case for Change at Illumina on "Close to the Edge"
Celebrating DNA: Matthew Cobb's Reflections on the Double Helix
The Sun Sets on AGBT: A Report from the Last Day